Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
4.44 | 0.07 (1.60%) |
| Exchange : | NASDAQ (US Dollar) |
| Ric Code : | ORMP |
| Volume : | 127,952 |
| Date : | 01-19-2021 |
* Minimum 20 minute delay See terms
–
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]
Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will [...]
Oramed Reports Positive First in Human Data from Oral Leptin Study
Leptin capsule may have a role in helping control and reduce obesity rates which are highly correlated with diabetes NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a [...]
Oramed Initiates Phase 2 NASH Trial of Oral Insulin
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first [...]
Oramed Initiates Phase 3 Trial of Oral Insulin
NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its [...]
Investors Tools